Critical Care Toxicology, 3 Teile

Center.

Dr Paul Dargan is a Consultant Physician and Clinical Toxicologist and Clinical Director at Guy's and St Thomas' NHS Foundation Trust, London, UK, and a Reader in Toxicology at King's College London. He has an active research and teaching programme with a focus on recreational drug toxicity, self-poisoning and heavy metal toxicity. He has published over 210 peer-reviewed papers and numerous book chapters. He sits on the UK Advisory Council on the Misuse of Drugs (ACMD), the Scientific Committee of the European Monitoring Centre for Drugs and Drugs Addiction EMCDDA) and is an expert adviser to a number of other bodies including the US Food and Drug Administration (FDA) and the World Health Organisation (WHO).

Dr. Hatten is an Assistant Professor of Emergency Medicine at the University of Colorado School of Medicine and Medical Toxicologist at the Rocky Mountain Poison and Drug Center in Denver, Colorado. He has an active toxicology practice in Denver and is academic faculty in the Medical Toxicology Fellowship and Emergency Medicine Residency at the University of Colorado.  In addition, he serves as an instructor in the Colorado School of Public Health. He underwent Medical Toxicology fellowship training and received a Master of Public Health at Oregon Health and Science University in Portland, Oregon. Prior to this, he completed Emergency Medicine residency training at Denver Health Medical Center in Denver, Colorado.  He is an alumni of the University of Texas-Southwestern School of Medicine in Dallas, Texas.  He also holds a Bachelor of Arts from Hendrix College in Conway, Arkansas. 

Bruno Megarbane is Professor of critical care medicine at Paris-Diderot University in Paris, France. He is the head of the Medical and Toxicological Intensive Care Unit, Lariboisière Hospital in Paris. His clinical researches focus at identifying prognostic factors and improving the management of severe poisonings including cardiotoxicant poisonings. He also actively participates to experimental researches at INSERM U1144, investigating the mechanisms of toxicity of psychotropic drugs like opioids and the new psychoactive substances. He is the President-elect of the European Association of Poison Centres and Clinical Toxicologists (EAPCCT). He is also an active member of the French Society of Intensive Care Medicine (SRLF), the European Society of Intensive Care Medicine (ESICM) and the American College of Medical Toxicology (ACMT). He is associate editor in Clinical Toxicology.

Dr. Palmer is a partner with the private practice Toxicology Associates in Denver, CO.  He completed a BS degree in chemistry at the University of Idaho, and MS and PhD degrees in organic-medicinal chemistry from the University of Washington.  He completed a NIDA postdoctoral fellowship at the University of Washington specializing in the pharmacology and medicinal chemistry of opioids, and a clinical toxicology fellowship at the Rocky Mountain Poison and Drug Center (RMPDC) in Denver, CO.  Dr. Palmer was previously faculty at the University of New Mexico Health Sciences Center, where he worked extensively with the Office of the Medical Investigator.  He is board-certified in clinical toxicology and currently president-elect of the American Academy of Clinical Toxicology.  He currently holds faculty appointments at the University of Wyoming, and University of Colorado School of Medicine, as well as serving as a faculty attending toxicologist for the medical toxicology fellowship program at the RMPDC.